Not finding it? Sign in to also search OpenAlex live.
-
Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial
Tsewang Tashi, Olivier Hermine, Mariana Castells, Mar Guilarte, Vito Sabato, Marcus Maurer, +26 more
19citations -
Domain Adaptation via Simulation Parameter and Data Perturbation for Predictive Maintenance2024 PHM Society European Conference conference-abstract Engineering Machine Fault Diagnosis Techniques Open access
Kiavash Fathi, Fabio Corradini, Marcin Sadurski, Marco Silvestri, Marko Ristin, Afrooz Laghaei, +3 more
0citations -
Artificial Intelligence Approach for the Discovery of Autoantigen Recognition By B-Cell Lymphomas2023 Blood conference-abstract Biochemistry, Genetics and Molecular Biology vaccines and immunoinformatics approaches
David Medina, Julieta Sepúlveda-Yáñez, Diego Álvarez-Saravia, Roberto Uribe-Paredes, Hendrik Veelken, Marcelo A. Navarrete
3citations -
A Machine Learning Approach to Upscale Net Ecosystem Exchange to a Regional Scale: Integration of Eddy Covariance, Remote Sensing and Reanalysis Data2020 conference-abstract Environmental Science Plant Water Relations and Carbon Dynamics Open access
Oliver Reitz, Alexander Graf, Marius Schmidt, Gunnar Ketzler, Michael Leuchner
0citations -
Filling the Gaps: Machine Learning Prediction of Sparse Mineral Phase Data2026 EGU General Assembly Conference Abstracts conference-abstract Materials Science Electron and X-Ray Spectroscopy Techniques Open access
Julia Schmitz, Joyce Schmatz, Mingze Jiang, Eva Wellmann, Mara Weiler, Friedrich Hawemann, +1 more
0citations -
Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial
Hartmut Goldschmidt, Eva Nievergall, Roland R. Fenk, Uta Bertsch, Diana Tichy, Britta Besemer, +25 more
33citations -
Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2
Hervé Avet‐Loiseau, Pieter Sonneveld, Philippe Moreau, Fritz C. Offner, Vincent H. J. van der Velden, Denis Caillot, +25 more
21citations -
Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
Hans Jürgen Salwender, Michael Hundemer, Uta Bertsch, Ema Požek, Axel Benner, Roland R. Fenk, +27 more
1citations -
Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial
Sonja Zweegman, Thierry T.F. Facon, Vânia Hungria, Nizar Jacques Bahlis, Christopher Paul Venner, Marc Justin Braunstein, +22 more
13citations -
Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor: ctDNA analysis from INTRIGUE.2023 Journal of Clinical Oncology conference-abstract Medicine Gastrointestinal Tumor Research and Treatment
Sebastian Bauer, Robin L. Jones, Suzanne George, Hans A. J. Gelderblom, Patrick Schöffski, Margaret von Mehren, +13 more
16citations -
Primary endpoint results of the phase 3b ASC4START trial of asciminib (ASC) vs nilotinib (NIL) in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP): Time to treatment discontinuation due to adverse events (TTDAE).
Andreas Hochhaus, François‐Xavier Mahon, Tim H. Brümmendorf, Phillipp D. Le Coutre, David Jacob Andorsky, Susanne Saußele, +14 more
6citations -
Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin
Larry Don Anderson, Jonathan L. Kaufman, Jacob P. Laubach, Douglas Weston Sborov, Brandi Reeves, Cesar Rodriguez, +21 more
3citations -
778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma2023 Regular and Young Investigator Award Abstracts conference-abstract Medicine Cancer Immunotherapy and Biomarkers Open access cited by 2 patents
Daniel J. Olson, James Larkin, Young Ki Hong, Sajeve Samuel Thomas, Juan Martín-Liberal, Andrew J.S. Furness, +13 more
3citations -
Outcomes in patients with advanced gastrointestinal stromal tumor who did not have baseline ctDNA detected in the INTRIGUE study.2023 Journal of Clinical Oncology conference-abstract Medicine Gastrointestinal Tumor Research and Treatment
Jonathan C. Trent, Robin L. Jones, Suzanne George, Hans A. J. Gelderblom, Patrick Schöffski, Margaret von Mehren, +13 more
2citations -
Abstract CT286: TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab vs pembrolizumab alone in treatment-naive unresectable or metastatic melanoma
Sajeve Samuel Thomas, Young Ki Hong, Yazan Samhouri, James Larkin, Gino Kim In, Victoria G. Atkinson, +21 more
2citations -
Safety and Preliminary Efficacy Results of a Novel Mesenchymal Stromal Cell Therapy in Diabetic Kidney Disease: The Multicenter, Randomized, Placebo-Controlled, Phase-1b/2a NEPHSTROM Clinical Trial2022 Journal of the American Society of Nephrology conference-abstract Medicine Mesenchymal stem cell research
Matthew Dallas Griffin, Giuseppe Remuzzi, Paul Cockwell, Alexander Peter Maxwell, Norberto Perico, Piero Luigi Ruggenenti, +6 more
0citations